Welcome to our dedicated page for Coeptis Therapeutics Holdings news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics Holdings stock.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company focused on developing cell therapy platforms for patients with cancer, autoimmune, and infectious diseases. The company's product portfolio includes multi-antigen CAR T technology known as SNAP-CAR, CD38-GEAR-NK cell therapy technology, and CD38-Diagnostic in vitro diagnostic for CD38-related cancers. Coeptis has strategic partnerships with Deverra Therapeutics, VyGen-Bio, the University of Pittsburgh, and the Karolinska Institutet to advance its innovative therapies. With a strong emphasis on research and development, Coeptis aims to revolutionize treatment paradigms and improve patient outcomes across various therapeutic areas.
FAQ
What is the current stock price of Coeptis Therapeutics Holdings (COEP)?
What is the market cap of Coeptis Therapeutics Holdings (COEP)?
What is Coeptis Therapeutics Holdings Inc focused on?
What are the key products in Coeptis' portfolio?
Who are some of Coeptis' strategic partners?
What is Coeptis' goal in their research and development efforts?
